UBS Group Begins Coverage on 10x Genomics (NASDAQ:TXG)
UBS Group Begins Coverage on 10x Genomics (NASDAQ:TXG)
UBS Group started coverage on shares of 10x Genomics (NASDAQ:TXG – Get Rating) in a research report released on Thursday, The Fly reports. The brokerage issued a neutral rating and a $50.00 price target on the stock.
據The Fly報道，瑞銀集團在週四發佈的一份研究報告中開始對10倍基因組(納斯達克：TXG-GET評級)的股票進行報道。該經紀公司對該股發佈了中性評級和50.00美元的目標價。
Several other analysts have also commented on TXG. The Goldman Sachs Group dropped their price target on shares of 10x Genomics from $35.00 to $25.00 and set a sell rating on the stock in a research report on Thursday, October 13th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of 10x Genomics in a research note on Tuesday, December 13th. They set a buy rating and a $50.00 target price on the stock. Morgan Stanley lowered their target price on shares of 10x Genomics from $70.00 to $64.00 and set an overweight rating on the stock in a research note on Friday, November 4th. Finally, JPMorgan Chase & Co. lowered their target price on shares of 10x Genomics from $65.00 to $55.00 in a research note on Thursday, November 3rd. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of Hold and an average target price of $50.90.
其他幾位分析師也對TXG發表了評論。10月13日，高盛夫婦在一份研究報告中將10x基因組公司的股票目標價從35.00美元下調至25.00美元，並對該股設定了賣出評級。德意志銀行Aktiengesellschaft在12月13日(星期二)的一份研究報告中假設了10倍基因組公司的股票。他們為該股設定了買入評級和50.00美元的目標價。摩根士丹利在11月4日(週五)的一份研究報告中將10倍基因的目標價從70美元下調至64美元，並對該股設定了增持評級。最後，摩根大通公司在11月3日星期四的一份研究報告中將10x基因組公司股票的目標價從65.00美元下調至55.00美元。兩名股票研究分析師將該股評級為賣出，兩名分析師給出了持有評級，六名分析師給出了該公司的買入評級。根據MarketBeat.com的數據，該股的普遍評級為持有，平均目標價為50.90美元。
10x Genomics Stock Down 3.6 %
10倍基因組學股票下跌3.6%
Shares of TXG traded down $1.79 during trading hours on Thursday, reaching $47.93. 111,934 shares of the company traded hands, compared to its average volume of 1,146,258. 10x Genomics has a 12-month low of $23.81 and a 12-month high of $99.14. The stock's fifty day moving average price is $39.36 and its 200 day moving average price is $35.90.
在週四的交易時段，TXG的股價下跌了1.79美元，達到47.93美元。該公司有111,934股易手，而平均成交量為1,146,258股。10倍基因組學的12個月低點為23.81美元，12個月高位為99.14美元。該股的50日移動均線價格為39.36美元，200日移動均線價格為35.90美元。
Insiders Place Their Bets
內部人士下注
In other news, insider Benjamin J. Hindson sold 2,361 shares of the firm's stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $80,439.27. Following the completion of the transaction, the insider now owns 217,713 shares in the company, valued at $7,417,481.91. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, insider Benjamin J. Hindson sold 2,361 shares of 10x Genomics stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $80,439.27. Following the transaction, the insider now directly owns 217,713 shares of the company's stock, valued at approximately $7,417,481.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Justin J. Mcanear sold 1,626 shares of 10x Genomics stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $34.07, for a total value of $55,397.82. Following the sale, the chief financial officer now owns 76,764 shares in the company, valued at $2,615,349.48. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,663 shares of company stock worth $227,008. 11.08% of the stock is owned by corporate insiders.
另一則消息是，內部人士本傑明·J·辛德森在11月22日星期二的一次交易中出售了2361股該公司股票。這隻股票的平均售價為34.07美元，總價值為80439.27美元。交易完成後，這位內部人士現在擁有該公司217,713股股票，價值7,417,481.91美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在這個環節。在其他新聞方面，內部人士本傑明·J·辛德森在11月22日星期二的交易中出售了2361股10倍基因組公司的股票。這隻股票的平均售價為34.07美元，總價值為80439.27美元。交易完成後，這位內部人士現在直接持有該公司217,713股股票，價值約7,417,481.91美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過美國證券交易委員會網站。此外，首席財務官賈斯汀·J·曼坎爾在11月22日(星期二)的一筆交易中出售了1,626股10倍基因組公司的股票。這隻股票的平均售價為34.07美元，總價值為55397.82美元。出售後，首席財務官現在擁有該公司76,764股，價值2,615,349.48美元。關於這次銷售的披露可以找到這裏。在上個季度，內部人士出售了6663股公司股票，價值227,008美元。11.08%的股份由企業內部人士持有。
Institutional Investors Weigh In On 10x Genomics
機構投資者參與10倍基因組學
A number of institutional investors and hedge funds have recently modified their holdings of TXG. Wipfli Financial Advisors LLC acquired a new position in 10x Genomics during the third quarter valued at $26,000. First Horizon Advisors Inc. boosted its stake in 10x Genomics by 14,780.0% during the 2nd quarter. First Horizon Advisors Inc. now owns 744 shares of the company's stock valued at $33,000 after purchasing an additional 739 shares during the period. Atlas Capital Advisors LLC boosted its stake in 10x Genomics by 45.5% during the 3rd quarter. Atlas Capital Advisors LLC now owns 1,360 shares of the company's stock valued at $39,000 after purchasing an additional 425 shares during the period. CWM LLC raised its holdings in 10x Genomics by 48.9% in the 4th quarter. CWM LLC now owns 1,185 shares of the company's stock valued at $43,000 after acquiring an additional 389 shares in the last quarter. Finally, Rockefeller Capital Management L.P. raised its holdings in 10x Genomics by 95.2% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 2,875 shares of the company's stock valued at $81,000 after acquiring an additional 1,402 shares in the last quarter. 74.34% of the stock is owned by institutional investors and hedge funds.
一些機構投資者和對衝基金最近調整了對TXG的持股。Wipfli Financial Advisors LLC在第三季度收購了10x基因組公司的一個新頭寸，價值2.6萬美元。第一地平線顧問公司(First Horizon Advisors Inc.)在第二季度將其在10倍基因組公司的持股增加了14,780.0%。First Horizon Advisors Inc.在此期間又購買了739股，現在持有744股該公司股票，價值3.3萬美元。Atlas Capital Advisors LLC在第三季度將其在10倍基因組公司的持股增加了45.5%。Atlas Capital Advisors LLC在此期間又購買了425股，現在擁有1360股該公司的股票，價值3.9萬美元。Cwm LLC在第四季度增持了10x基因組學48.9%的股份。Cwm LLC在上個季度增持了389股後，現在擁有1185股該公司股票，價值4.3萬美元。最後，洛克菲勒資本管理公司(Rockefeller Capital Management L.P.)在第三季度將其在10倍基因組公司的持股增加了95.2%。洛克菲勒資本管理公司(Rockefeller Capital Management L.P.)在上個季度增持了1,402股股票後，現在持有該公司2,875股股票，價值81,000美元。74.34%的股票由機構投資者和對衝基金持有。
10x Genomics Company Profile
10倍基因組學公司簡介
(Get Rating)
(獲取評級)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
10x基因公司是一家生命科學技術公司，在北美、歐洲、中東、非洲、中國和亞太地區開發和銷售用於分析生物系統的儀器、消耗品和軟件。本公司提供鉻及鉻連接儀器、微流控芯片、載玻片、試劑等耗材產品。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on 10x Genomics (TXG)
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- Nvidia Rallies As Investors Bullish On Chipmaker's AI Business
- Bright Green Corporation Future May be Getting Brighter
- Microsoft Fast Integrating AI Into Enterprise & Healthcare Suites
- 免費獲取StockNews.com關於10x基因組學(TXG)的研究報告
- 福特股票在盈利大幅下滑後繼續前進
- 內部人士和機構收購金剛狼全球
- 英偉達股價上漲，投資者看好芯片製造商的人工智能業務
- 光明綠色公司的未來可能變得更加光明
- 微軟將人工智能快速集成到企業和醫療保健套件中
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得10倍基因組學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對10x基因組學和相關公司的最新新聞和分析師評級的每日簡明摘要。